BioPharma Services Inc.
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets
Role: collaborator
Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.
Role: collaborator
Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions
Role: collaborator
Bioequivalence Study of Tacrolimus in Healthy Volunteers
Role: collaborator
A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics
Role: collaborator
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
Role: collaborator
All 6 trials loaded